Bryan G. Johnson - Concepedia

Concepedia

Author

Bryan G. Johnson

Eli Lilly (United States)

Also Known As

B G Johnson, B. G. JOHNSON, B. G. Johnson, B.G JOHNSON, B.G Johnson, B.G. Johnson, Bryan G Johnson, Bryan G. Johnson, Bryan Johnson, Johnson, B.G.

76

Publications

5.8K

Citations

38

H-Index

62

Concepts

All Affiliations

Eli Lilly (United States)Eli Lilly (United Kingdom)Universidad San Pablo CEU

BG

About

Bryan G. Johnson is an author at Eli Lilly (United States) specializing in medicine, neuropharmacology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	41	4.3K
2	Social Sciences	15	16	2.2K
3	Natural Sciences	11	12	1.1K
4	Health Sciences	4	4	113
5	Allergy	2	2	73

Bryan G. Johnson

×

58

Publications

5.8K

Citations

38

H-Index

	Year	Citations
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial Sandeep T. Patil, Lu Zhang, Ferenc Martényi, Nature Medicine PsychiatryPsychotic DisorderMedicinePsychotropic MedicationMglu2/3 Receptors	2007	1K
Design, Synthesis, and Pharmacological Characterization of (+)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY354740): A Potent, Selective, and Orally Active Group 2 Metabotropic Glutamate Receptor Agonist Possessing Anticonvulsant and Anxiolytic Properties James A. Monn, Matthew J. Valli, Steven M. Massey, Journal of Medicinal Chemistry Pharmacological CharacterizationActive Group 2Psychotropic MedicationPharmacotherapyChemical Biology	1997	392
LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors Anne Kingston, Paul L. Ornstein, Rebecca A. Wright, Neuropharmacology Functional SelectivityMedicineDrug DiscoveryMechanism Of ActionReceptor (Biochemistry)	1998	364
Synthesis, Pharmacological Characterization, and Molecular Modeling of Heterobicyclic Amino Acids Related to (+)-2-Aminobicyclo[3.1.0]hexane- 2,6-dicarboxylic Acid (LY354740): Identification of Two New Potent, Selective, and Systemically Active Agonists for Group II Metabotropic Glutamate Receptors James A. Monn, Matthew J. Valli, Steven M. Massey, Journal of Medicinal Chemistry Active AgonistsMglu ReceptorsPharmacotherapyChemical BiologyPharmaceutical Chemistry	1999	286
3,5‐Dihydroxyphenylglycine Is a Highly Selective Agonist for Phosphoinositide‐Linked Metabotropic Glutamate Receptors in the Rat Hippocampus Darryle D. Schoepp, John Goldsworthy, Bryan G. Johnson, Journal of Neurochemistry	1994	269
LY354740 is a Potent and Highly Selective Group II Metabotropic Glutamate Receptor Agonist in Cells Expressing Human Glutamate Receptors Darryle D. Schoepp, Bryan G. Johnson, Rebecca A. Wright, Neuropharmacology Functional SelectivityMedicineNeurotransmitterNeuropharmacologyNeuroscience	1997	225
Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (–)-(1 R, 4 S,5 S,6 S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039) Matthew Fell, Kjell Svensson, Bryan G. Johnson, Journal of Pharmacology and Experimental Therapeutics	2008	206
Excitatory Amino Acid Agonist‐Antagonist Interactions at 2‐Amino‐4‐Phosphonobutyric Acid‐Sensitive Quisqualate Receptors Coupled to Phosphoinositide Hydrolysis in Slices of Rat Hippocampus Darryle D. Schoepp, Bryan G. Johnson Journal of Neurochemistry	1988	179
Inhibition of Cyclic AMP Formation by a Selective Metabotropic Glutamate Receptor Agonist Darryle D. Schoepp, Bryan G. Johnson, James A. Monn Journal of Neurochemistry Cyclic Amp FormationSynaptic TransmissionNeurotransmitterPharmacotherapySocial Sciences	1992	156
In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders Linda M. Rorick‐Kehn, Bryan G. Johnson, Karen M. Knitowski, Psychopharmacology Molecular PharmacologyPsychoactive DrugPsychiatric DisordersPsychiatryMedicine	2007	156

Page 1